Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 13/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 13/20 | 0.40 |
| ▸ | PPARD | Q03181 | 13/20 | 0.40 |
| ▸ | PPARA | Q07869 | 11/20 | 0.39 |
| ▸ | PPARG | P37231 | 7/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035524 | 0.91 | PPARD (0.43) | NR1H2NR1H3PPARDPPARAPPARG | |
| SCHEMBL6035430 | 0.91 | PPARD (0.41) | NR1H2NR1H3PPARDPPARAPPARG | |
| SCHEMBL6035664 | 0.91 | PPARD (0.41) | NR1H2NR1H3PPARDPPARAPPARG | |
| SCHEMBL6035112 | 0.89 | PPARD (0.42) | NR1H2NR1H3PPARDPPARAPPARG | |
| SCHEMBL6035712 | 0.88 | PPARG (0.44) | NR1H2NR1H3PPARDPPARAPPARG | |
| SCHEMBL6036423 | 0.87 | PPARD (0.40) | NR1H2NR1H3PPARDPPARAPPARG | |
| SCHEMBL6035959 | 0.86 | PLA2G4B (0.42) | NR1H2NR1H3PPARDPPARAPPARG | |
| SCHEMBL6034621 | 0.86 | PPARG (0.39) | NR1H2NR1H3PPARDPPARAPPARG | |
| SCHEMBL6035863 | 0.85 | PPARD (0.41) | PPARDPPARAPPARG | |
| SCHEMBL6034663 | 0.85 | PPARG (0.44) | NR1H2NR1H3PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | NR1H2 12/4885NR1H3 4/4885PPARD 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.